Trial reportCancer reports (Hoboken, N.J.)2022
Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Trial report in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Sumac-rose water mouthwash versus benzydamine to prevent radiation-induced oral mucositis in head and neck cancers: a phase II randomized trial.Journal of cancer research and clinical oncology · 2023Trial
- Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.Cancer reports (Hoboken, N.J.) · 2022Trial
- Effects of Hydrogen Water Gargling on Oral Mucositis and Pain in Head and Neck Cancer Patients: A Randomized Controlled Pilot Study.Integrative cancer therapiesTrial
- At-home 1-week hydration improves tolerance and treatment intensity of high-dose cisplatin in locally advanced head and neck cancer: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Exploratory Research: Patient-Reported Factors Contributing to Decreased Oral Intake During Radiotherapy in Head and Neck Cancer.Head & neck · 2025Article
- Clinical and Dosimetric Predictors of Early Onset Postradiation Hypothyroidism in Patients with Head and Neck Malignancies: A Logistic Regression Analysis.Oncology and therapy · 2025Article
- Review
- Exploring TSGA10 Function: A Crosstalk or Controlling Mechanism in the Signaling Pathway of Carcinogenesis?Cancers · 2024Review
- A new approach to prevent radiation-induced xerostomia using intraglandular injection of mitochondria-boosting agents.BMC cancer · 2024Article
- Expectations and Experiences of Participating in a Supervised and Home-Based Physical Exercise Intervention in Patients with Head and Neck Cancer during Chemoradiotherapy: A Qualitative Study.Current oncology (Toronto, Ont.) · 2024Article
- Intra-Parotid Recurrent Nasopharyngeal Carcinoma Following Intensity-Modulated Radiation Therapy: A Case Report.Clinical medicine insights. Case reports · 2024Article
- Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide.Cancers · 2022Review
- A novel biocompatible Eu-based coordination polymers of cytarabine anticancer drug: Preparation, luminescence properties andFrontiers in chemistry · 2022Article
- Precision medicine for risk prediction of oral complications of cancer therapy-The example of oral mucositis in patients receiving radiation therapy for cancers of the head and neck.Frontiers in oral health · 2022Review
- Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients.Radiation oncology (London, England) · 2021Article
- Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma.Clinical Medicine Insights. Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current first-line treatment of locally advanced head and neck carcinoma (LAHNC) is concurrent chemoradiation with three-weekly cisplatin 100 mg/m
aimTo compare the acute hematologic and renal toxicities of these two regimens.
methodsThis randomized clinical trial included 77 LAHNC patients who were allocated to a high dose (100 mg/m
resultsThe average age of patients was 55.3 years. Overall, 71.4% of patients were treated in a definitive setting. The incidence of severe hematologic events was not significantly different. However, the average estimated glomerular filtration rate (eGFR) was significantly greater in the three-weekly group (67.85 vs. 58.57% mL/min per 1.73 m
conclusionsSevere acute hematologic toxicities were comparable for three-weekly and weekly groups. The decrease in eGFR through treatment was more significant with weekly cisplatin. Further follow-up, however, is needed to confirm its impact on delayed renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.